摘要:
The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
摘要:
The present invention is directed to novel 3-piperidin-4-yl-indole derivatives of formula (I) and forms thereof, wherein X, R1, R2, R3, R4 and R5 are as herein defined, pharmaceutical compositions thereof and use as ORL-1 receptor modulators for treating, preventing or ameliorating ORL-1 receptor mediated disorders and conditions.
摘要翻译:本发明涉及新的式(I)的3-哌啶-4-基 - 吲哚衍生物及其形式,其中X,R 1,R 2,R R 4,R 4和R 5如本文所定义,其药物组合物用作ORL-1受体调节剂,用于治疗,预防或改善 ORL-1受体介导的病症和病症。
摘要:
The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
摘要:
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective α1a/α1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.
摘要:
The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
摘要:
A device for directly securing the heel of the foot of a wearer to the interior of a rear heel cap of a shoe. The device can include a first portion for adhering directly to the skin of the heel of the wearer's foot. The device can include a second portion for adhering directly to the material of the interior heel of the shoe. The device can be particularly useful in connection with shoes leaving the upper portion of the foot exposed without securing straps and having high heels. The device is subject to a shear force between the first and second portions when worn as opposed to a tensile force more commonly exhibited when a base of an implement is attached to the sole of a shoe.
摘要:
A single rapid procedure for the quantitative and qualitative analysis of flavonoid glycosides and steroidal glycosides, in natural products, has been developed. The material is extracted with aqueous solutions of polar organic solvents in an ultrasonic bath. Interfering compounds are removed by pre-purification procedures prior to instrumental analysis by High Pressure Liquid Chromatography with Negative Ion Electrospray Mass Spectrometric Detection and on-line Diode Array Ultraviolet-Visible Spectroscopy. The analysis of flavonoid and steroidal glycosidic compounds in HOSTA leaves served as a model system.
摘要:
A method and system are provided. The method includes calculating respective moving average values for client holdings at a financial account level, an individual client level, and a household level based on end-of-day holding prices therefor. The method further includes calculating a financial account level risk metric, an individual level risk metric, and a household level risk metric responsive to the respective moving average values. The method also includes outputting a respective alarm signal for at least one financial firm employee responsive to any of the financial account level risk metric, the individual level risk metric, and the household level risk metric respectively exceeding a target financial account level risk metric, a target individual level risk metric, and a target household level risk metric. The target risk metrics are determined from respective client specified risk acceptance values at the financial account level, the individual client level, and the household level.